Alnylam Pharmaceuticals, Inc.

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC ALNY

Report date

12/31/2025

Quarter

2025 Q4

Filed

2/13/2026

Shares

652,366

Value ($000)

259,413

Weight

0.1%

2013 Q4 - 2025 Q4 (27 filings)

Shares History

History scope: non-option holdings only (PUT/CALL rows excluded).

All 13F Holders	Filing date	Value ($000s)	% of Holdings	Shares	Reporting period
2025 Q4	2/13/2026	259,413	0.1%	652,366	12/31/2025
2025 Q3	11/14/2025	323,105	0.1%	708,564	9/30/2025
2025 Q2	8/14/2025	312,504	0.1%	958,336	6/30/2025
2025 Q1	5/19/2025	198,765	0.1%	736,111	3/31/2025
2024 Q4	2/14/2025	167,211	0.0%	710,598	12/31/2024
2024 Q3	11/14/2024	194,235	0.0%	706,231	9/30/2024
2024 Q2	8/14/2024	203,005	0.1%	835,413	6/30/2024
2024 Q1	5/15/2024	113,380	0.0%	758,650	3/31/2024
2023 Q4	2/14/2024	141,846	0.1%	741,061	12/31/2023
2023 Q3	11/13/2023	137,160	0.1%	774,476	9/30/2023
2023 Q2	8/11/2023	134,991	0.1%	673,878	6/30/2023
2023 Q1	5/15/2023	134,991	0.1%	673,878	3/31/2023
2022 Q4	2/14/2023	156,355	0.1%	657,920	12/31/2022
2022 Q3	11/14/2022	120,803	0.1%	603,532	9/30/2022
2022 Q2	8/12/2022	86,521	0.0%	593,222	6/30/2022
2022 Q1	5/16/2022	98,817	0.0%	605,165	3/31/2022
2021 Q4	2/14/2022	108,652	0.0%	640,710	12/31/2021
2021 Q3	11/15/2021	121,890	0.1%	645,572	9/30/2021
2021 Q2	8/16/2021	105,650	0.0%	623,228	6/30/2021
2021 Q1	5/14/2021	93,966	0.0%	665,529	3/31/2021
2020 Q4	3/1/2021	91,685	0.0%	705,435	12/31/2020
2020 Q3	11/13/2020	105,302	0.1%	723,225	9/30/2020
2020 Q2	8/14/2020	124,061	0.1%	837,627	6/30/2020
2020 Q1	5/15/2020	90,496	0.1%	831,386	3/31/2020
2019 Q4	2/14/2020	94,862	0.1%	823,669	12/31/2019
2014 Q1	5/23/2014	112,115	0.1%	1,669,861	3/31/2014
2013 Q4	1/31/2014	102,060	0.1%	1,586,502	12/31/2013